Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

399

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

December 1, 2021

Conditions
Severe COVID-19 Pneumonia
Interventions
DRUG

IFX-1 + BSC

Phase II study part: IFX-1 + BSC

DRUG

BSC

Phase II study part: BSC

DRUG

IFX-1 + SOC

Phase III study part: IFX-1 + SOC

DRUG

Placebo + SOC

Phase III study part: Placebo + SOC

Trial Locations (48)

Unknown

InflaRx Site #1107, Aalst

InflaRx Site #1102, Brussels

InflaRx Site #1104, Leuven

InflaRx Site #1106, Lodelinsart

InflaRx Site #1101, Yvoir

InflaRx Site #0301, Belo Horizonte

InflaRx Site #0302, Campinas

InflaRx Site #0305, Criciúma

InflaRx Site #0308, Curitiba

InflaRx Site #0304, Porto Alegre

InflaRx Site #0303, São José

InflaRx Site #0306, São Paulo

InflaRx Site #1011, Grenoble

InflaRx Site #1005, Nantes

InflaRx Site #1009, Nantes

InflaRx Site #1003, Nice

InflaRx Site #1001, Paris

InflaRx Site #1004, Paris

InflaRx Site #1006, Paris

InflaRx Site #1008, Paris

InflaRx Site #1012, Saint-Etienne

InflaRx Site #1002, Suresnes

InflaRx Site #0201, Aachen

InflaRx Site #0207, Augsburg

InflaRx Site #0202, Berlin

InflaRx Site #0208, Dresden

InflaRx Site #0204, Essen

InflaRx Site #0203, Greifswald

InflaRx Site #0205, Hanover

InflaRx Site #0206, Jena

InflaRx Site #0502, Chihuahua City

InflaRx Site #0503, Culiacán

InflaRx Site #0506, Mérida

InflaRx Site #0504, Monterrey

InflaRx Site #0501, Nuevo León

InflaRx Site #0505, Veracruz

InflaRx Site #0101, Amsterdam

InflaRx Site #0103, Amsterdam

InflaRx Site #0106, Eindhoven

InflaRx Site #0104, Enschede

InflaRx Site #0102, Maastricht

InflaRx Site #0601, Callao

InflaRx Site #0603, Lima

InflaRx Site #0604, Lima

InflaRx Site #0701, Barnaul

InflaRx Site #0704, Moscow

InflaRx Site #0702, Ryazan

InflaRx Site # 0804, Somerset West

Sponsors

Lead Sponsor

All Listed Sponsors
lead

InflaRx GmbH

INDUSTRY

NCT04333420 - Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter